Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC
CompanyDrug

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Merck & Co., Inc. (MSD; NYSE: MRK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa‑pmph), a subcutaneous formulation of its…

Roche's Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Roche’s Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

CompanyDeals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

CompanyDeals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

CompanyDrug

NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment

CompanyDrug

Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval

CompanyDeals

Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen

CompanyDrug

Jiangsu Hengrui’s Fluzoparib Gains NMPA Approval as Maintenance Therapy for Ovarian Cancer

CompanyDrug

Sichuan Biokin’s BL-B01D1 Advances to Phase III for HR+/HER2- Breast Cancer

Show More